|
Originally published In Press as doi:10.1074/jbc.M105325200 on September 10, 2001
J. Biol. Chem., Vol. 276, Issue 46, 43455-43462, November 16, 2001
Apolipoprotein E Inhibits Serum-stimulated Cell Proliferation and
Enhances Serum-independent Cell Proliferation*
Yuan-Yuan
Ho §,
Richard J.
Deckelbaum ¶,
Yachi
Chen ,
Tikva
Vogel**, and
David A.
Talmage ¶
From the Institute of Human Nutrition and the
¶ Department of Pediatrics, Columbia University, New York, New
York 10032 and ** Biotechnology General Limited,
Rehovot 76326, Israel
Received for publication, June 8, 2001, and in revised form, September 6, 2001
 |
ABSTRACT |
Independently of its role in lipid homeostasis,
apolipoprotein E (apoE) inhibits cell proliferation. We compared the
effects of apoE added to media (exogenous apoE) with the effects of
stably expressed apoE (endogenous apoE) on cell proliferation.
Exogenous and endogenous apoE increased population doubling times by
30-50% over a period of 14 days by prolonging the
G1 phase of the cell cycle. Exogenous and endogenous
apoE also decreased serum-stimulated DNA synthesis by 30-50%.
However, apoE did not cause cell cycle arrest; both apoE-treated and
control cells achieved equivalent saturation densities at 14 days.
Further analyses demonstrated that exogenous and endogenous apoE
prevented activation of MAPK but not induction of c-fos
expression in response to serum growth factors. Endogenous (but not
exogenous) apoE altered serum concentration-dependent effects on proliferation. Whereas control (non-apoE-expressing) cell
numbers increased with increasing serum concentrations (1.6-fold for
every 2-fold increase in serum), apoE-expressing cell numbers did not
differ as serum levels were raised from 2.5 to 10%. In addition, in
low serum (0.1%), apoE-expressing cells had elevated DNA synthesis
levels compared with control cells. We conclude that apoE does not
simply inhibit cell proliferation; rather, the presence of apoE alters
the response to and requirement for serum mitogens.
 |
INTRODUCTION |
Apolipoprotein E (apoE)1
plays an important role in the progression of atherosclerosis (1), and
different isoforms are associated with varying risks of Alzheimer's
disease (2). ApoE is a major protein component of several classes of
plasma lipoproteins and is capable of binding to a number of other
molecules, including cell-surface lipoprotein receptors and heparan
sulfate proteoglycans (1, 3). Although apoE can also influence cell
proliferation (4-6), research efforts have focused on determining the
mechanisms by which apoE affects lipid metabolism, specifically by
facilitating lipoprotein transport, promoting cell cholesterol efflux,
and enhancing intracellular cholesteryl ester and triglyceride
hydrolysis (7-10).
ApoE can reach cells from two sources: exogenous apoE (defined as apoE
synthesized or provided by a remote source such as plasma apoE or apoE
added to experimental media), usually as a component of lipoproteins,
or endogenous apoE (defined as apoE produced by cellular apoE gene
expression). Since apoE binds to lipids and other molecules (1, 3, 11),
exogenous apoE and endogenous apoE can potentially encounter and
interact with different groups of molecules in the extracellular
environment compared with the intracellular environment. For example,
exogenous apoE binds to cell-surface apoE receptors and mediates
endocytosis, whereas endogenous apoE is mainly associated with Golgi
compartments (1, 12). Thus, it is likely that following endogenous
synthesis, apoE has different effects on cell function compared with
apoE entering cells from the extracellular environment. In macrophages, exogenous apoE is much less effective than endogenous apoE in promoting
cholesterol efflux (7, 13). Although exogenous apoE and endogenous apoE
are capable of interacting with cells differently, they both can bind
the same cell-surface components such as heparan sulfate proteoglycans
(3), thereby exerting similar biological effects.
Exogenous apoE affects the proliferation of various cell types (4-6).
Cell proliferation is controlled by protein kinase-based signaling
pathways linking cell-surface mitogen receptors with various targets
within the cell, including critical transcription regulators. Exogenous
apoE has been shown to affect the activities of several protein kinases
known to be involved in transmitting mitogenic stimuli, including
protein kinases A and C and mitogen-activated protein kinases (MAPKs)
(6). On the other hand, endogenous apoE expression is controlled by
growth state (14), and/or it is tightly coupled to cell differentiation
(15, 16). Endogenous apoE also alters cellular signaling and protein
kinase activity (17, 18). The question of whether exogenous apoE and
endogenous apoE have similar effects on cell proliferation or
differentiation has not been addressed directly in the same cell type.
Previous studies have examined the inhibitory effects of exogenous apoE
on short-term cell proliferative responses in the presence of serum
stimuli (4-6). In this study, we determined the effects of exogenous
apoE and endogenous apoE on cell proliferation under conditions of both
serum deprivation and serum stimulation. To compare the effects of
exogenous apoE and endogenous apoE on proliferation in the same cell
type, we stably expressed apoE in a rat fibroblast cell line (F111
cells) that normally does not express apoE. The proliferation
properties of parental F111 cells have been previously characterized in
detail (19-21). Cells expressing the apoE transgene were defined as
E+ cells, in contrast to E cells carrying
only the control plasmid (encoding hygromycin resistance). Responses of
cells to serum were determined in the presence or absence of exogenous
apoE. Our results indicate that although exogenous apoE and endogenous
apoE exhibit similar effects on cell proliferation at a fixed serum
concentration, cell proliferative responses to apoE differ dramatically
under serum-deprived versus serum-stimulated conditions.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Purified lipid-free apoE was used for
experiments. [3H]Thymidine and ECL Western blotting
reagents were purchased from Amersham Pharmacia Biotech, and
[32P]dCTP was purchased from PerkinElmer Life Sciences.
High-glucose (4.5 mg/ml) Dulbecco's modified Eagle's medium (DMEM)
was obtained from Cellgro (carried by Fisher). Calf serum was obtained
from Hyclone Laboratories (Logan, UT).
Penicillin/streptomycin/glutamine mixture (100×: 10,000 units/ml
penicillin G sodium, 10,000 µg/ml streptomycin sulfate, 29.2 mg/ml
L-glutamine, and 10 mM sodium citrate in 0.14%
NaOH) and trypsin were purchased from Life Technologies, Inc.
Phosphate-buffered saline (PBS), diethyl pyrocarbonate, and CsCl2 were purchased from Sigma. Hygromycin B was purchased
from Roche Molecular Biochemicals. Monoclonal anti-phosphotyrosine antibody 4G10 was obtained from Upstate Biotechnology, Inc. (Lake Placid, NY). Polyclonal anti-MAPK and monoclonal anti-phospho-MAPK antibodies were purchased from New England Biolabs Inc. (Beverly, MA).
Monoclonal anti-apoE antibody E10 was a generous gift from Drs. E. Krul
and G. Schonfield (University of Washington). Horseradish peroxidase-labeled secondary antibodies were purchased from Amersham Pharmacia Biotech and New England Biolabs Inc.
Plasmids--
An apoE expression vector in which the human apoE3
cDNA is expressed from the cytomegalovirus immediate-early promoter
was a generous gift from Dr. T. Mazzone (University of Chicago) (33). The hygromycin resistance gene cloned into the plasmid p hygro was
regulated by the rat actin promoter (34). Plasmids were transfected
into competent Escherichia coli strain DH5 and purified on
QIAGEN columns or by CsCl2/EtBr banding (35).
Cells--
Rat F111 embryonic fibroblasts were maintained in
high-glucose DMEM containing 10% calf serum and 100 units/ml
penicillin G sodium plus 100 µg/ml streptomycin sulfate.
ApoE-expressing cell lines were generated by cotransfecting F111
fibroblasts with the apoE3 expression vector and p hygro using
calcium phosphate-mediated DNA precipitation (36). Control cell lines
were generated in parallel by transfecting the parental cells with
p hygro alone. Hygromycin-resistant cells were selected for 1 week in
high-glucose DMEM supplemented with 10% calf serum, 100 units/ml
penicillin G sodium plus 100 µg/ml streptomycin sulfate, and 200 µg/ml hygromycin and then maintained in the same medium with reduced
hygromycin concentrations (100 µg/ml). Three apoE-expressing
(E+) and three control (E ) clones were
expanded into cell lines and used for experiments. Similar results were
obtained with each clone.
Immunoblots--
For detection of apoE synthesis and secretion,
cells (60% confluence) were cultured for 24 h in serum-free
medium. Both the conditioned medium (concentrated by Amicon Centriprep
concentrators, molecular mass cutoff of 10,000 Da) and whole cell
extracts (following lysis in 150 mM NaCl, 1%
Nonidet P-40, and 50 mM Tris, pH 8.0) were resolved by
SDS-12% polyacrylamide gel electrophoresis, followed by
electrophoretic transfer of proteins to nitrocellulose membranes. ApoE
was detected by incubating membranes with the monoclonal anti-human
apoE antibody (E10, 1:2000 dilution in Tris-buffered saline, 0.1%
(v/v) Triton X-100, 1% (w/v) nonfat milk, and 0.1% (w/v) sodium
azide). Bound primary antibodies were visualized with horseradish
peroxidase-conjugated rabbit anti-mouse secondary antibodies and ECL
reactions (37). To determine MAPK activity, cell extracts were resolved
electrophoretically on SDS-10% polyacrylamide gels and transferred to
membranes that were probed with primary antibodies specific to MAPK
(1:2000 dilution) or phosphorylated MAPK (1:2000 dilution), followed by
incubation with horseradish peroxidase-labeled secondary antibodies and
ECL reactions for the detection of total and activated MAPK levels.
Microscopy--
Cell morphology was examined under an Olympus
CK2 inverted microscope, and images were recorded by an Olympus
C-35-AD-4 camera. The differential interference contrast images were
taken under magnification × 100. For experiments aimed to
identify the Golgi regions, cells maintained in coverslip bottom
dishes were fixed and incubated with 10 mM
NBD-C6 dissolved in DMEM containing 0.68 mg/ml fatty
acid-free bovine serum albumin for 20 min at 37 °C. Cells were then
washed with DMEM for 30 min at 37 °C and submitted for imaging
analysis. For identifying the intracellular neutral lipid, cells in
coverslip bottom dishes were incubated with 100 ng/ml Nile red and
observed immediately. For apoE immunostaining, cells in coverslip
bottom dishes were fixed for 30 min with 2% formaldehyde and then
washed four times with PBS. Cells were permeabilized with saponin (5%
calf serum, 500 µg/ml saponin, and 20 mM glycine in PBS)
for 20 min. Prior to incubation, the anti-apoE antibody was
pre-absorbed with E cell protein extracts to reduce
nonspecific binding. ApoE immunodetection was performed as follows: 1)
monoclonal anti-apoE primary antibody E10 (1:200 dilution) incubation
(1 h); 2) three washes with 5% calf serum and 500 µg/ml saponin in
PBS (5 min/wash); 3) rhodamine-conjugated goat anti-mouse IgG secondary
antibody (1:500 dilution in 5% calf serum and 500 µg/ml saponin in
PBS) incubation (1 h); and 4) two washes with 5% calf serum and 500 µg/ml saponin in PBS (5 min/wash) and one wash with PBS (10 min). For
actin staining, formaldehyde-fixed cells were extracted by acetone
( 20 °C, 3-5 min), followed by two PBS washes and a 25-min
incubation in PBS and 1% bovine serum albumin blocking solution. Cells
were then stained with actin-BODIPY FL phallacidin (Molecular
Probes, Inc., Eugene, OR) at 1:40 dilution in PBS and 1% bovine serum
albumin for 20 min. Fluorescent images were obtained using a Zeiss
LSM410 confocal laser scanning system attached to a Zeiss Axiovert
100TV inverted microscope. For observation of fluorescence signals
based on the excitation/emission wavelengths of the dyes (rhodamine,
570/590 nm; Nile red, 552/636 nm; NBD-C6, 466/536
nm; and phallacidin, 505/512 nm), appropriate combinations of
excitation laser and emission filter settings were used. Images were
recorded with a Pentium PC computer with Zeiss LSM software for image
enhancement and analysis.
Cell Proliferation Rates--
Cells (500/well) were plated in
12-well tissue culture plates (Corning Inc., Corning, NY), and cell
number was determined from days 3 to 14. Media (with or without apoE)
were changed every 3 days throughout the course of the experiments. For
cells incubated with exogenous apoE, 10 µg/ml purified lipid-free
apoE was added at every media change (every 3 days). At the indicated
time points, cells were trypsinized and detached from the plates, and
cell number was counted using a hemocytometer. Results represent three parallel experiments.
Fluorescence-activated Cell Sorter Analyses--
105
cells suspended in 50 µl of PBS with 3% calf serum were mixed with 1 ml of 80% ethanol and incubated at 4 °C for 30 min. Cells were then
pelleted and resuspended in 500 µl of 0.1 mg/ml propidium iodide and
0.6% Nonidet P-40, followed by incubation with 500 µl of 2 mg/ml
RNase A at room temperature for 30 min in the dark.
DNA Synthesis--
For experiments measuring DNA synthesis, 1 µCi/ml [3H]thymidine was added to the experimental
medium and incubated with cells for 40 h to label the newly
synthesized DNA. At the end of the incubation, cells were placed on ice
and washed twice with ice-cold PBS, and cell macromolecules including
DNA were precipitated for 1 h with ice-cold 10% trichloroacetic
acid. Cell precipitates were washed twice with ice-cold 10%
trichloroacetic acid to remove free [3H]thymidine and
then dissolved in 1 N NaOH (37 °C, 2 h).
Trichloroacetic acid-insoluble radioactivity was quantified by
scintillation counting. Experiments were repeated three times, and
similar results were obtained.
RNA Extraction and Gel Electrophoresis--
Cells were plated in
100-mm tissue culture dishes in the growth medium overnight. After
experimental treatments (2.5% calf serum ± 10 µg/ml apoE),
cells were washed twice at room temperature with 0.1% diethyl
pyrocarbonate-treated PBS and then harvested in Trizol reagent (3 ml/dish; Life Technologies, Inc.). RNA was extracted following the
manufacturer's instructions. RNA concentration was determined by
spectrophotometry at A260. RNA (10 µg/lane) was dissolved
in water and ethidium bromide-containing sample buffer (5 Prime 3 Prime, Inc., Boulder, CO), followed by boiling in a water bath for 5 min. Samples were loaded and resolved on 1.2% agarose gels (containing
40 mM MOPS, pH 7.0, 10 mM acetate, and 1.1 M formaldehyde) for 4 h at 100 V. After
electrophoresis, the gels were examined under UV light to ensure
equivalent RNA loading and integrity. Gels were then gently washed at
room temperature with diethyl pyrocarbonate-treated water for 30 min to remove ethidium bromide.
Northern Blot Analyses--
RNA samples on gels were transferred
to nylon membranes (Stratagene, La Jolla, CA) in 10× SSC (1.5 M NaCl and 0.15 M trisodium citrate-2H2O, pH 7.0) overnight. The membranes were then
irradiated with UV light (1200 J) to cross-link the RNA to the
membrane. 32P-Labeled DNA probes were prepared by the
random priming method (38) using [ -32P]dCTP. Nylon
membranes were prehybridized for 15 min and hybridized to radioactively
labeled c-fos or L30 probes for 1 h at 65 °C in
QuikHyb hybridization solution (Stratagene) and 100 µg/ml salmon sperm DNA. Membranes were washed twice (15 min/wash) with 2× SSC containing 0.1% (w/v) SDS at room temperature and with 0.1× SSC containing 0.1% SDS at 60 °C for 30 min. Dried membranes were exposed to Kodak XAR-5 film with intensifying screens at 70 °C. Hybridization intensities were quantified by a PhosphorImager (Molecular Dynamics, Inc., Sunnyvale, CA). The intensity of the c-fos mRNA signal was normalized for possible
differences in mRNA loading or transfer by dividing its value by
the intensity of the L30 ribosomal protein mRNA.
Statistical Analysis--
Unpaired t tests were
performed to test the differences between the groups (with exogenous
apoE versus without exogenous apoE or E cells
versus E+ cells). A significance of difference
was determined at the p < 0.05 level.
 |
RESULTS |
Isolation of ApoE-expressing Cell Lines--
To compare the
effects of exogenous apoE added to cells via the culture medium with
the effects of endogenous apoE (synthesized in and secreted from
cells), we established stably transfected derivatives of the rat F111
embryonic fibroblast cell line. Multiple clones were isolated that
expressed either apoE and hygromycin resistance (referred to as
E+ cells) or hygromycin resistance only (referred to as
E cells). We confirmed that E+ cells
synthesized and secreted apoE by immunoblot analyses of whole cell
extracts and concentrated conditioned medium from these clones (Fig.
1A) and by indirect
immunofluorescence (Fig. 1B). E+ cells
synthesized and secreted an ~34-kDa protein that comigrated with
purified apoE. Based on the signal intensities of apoE standards obtained in these immunoblots, we estimate that E+ cells
secrete ~40 ng of apoE/106 cells/day and contain ~25 ng
of intracellular apoE/mg of total cell protein. No apoE, either
intracellular or secreted, was detected in E cell
cultures. Although E+ cells clearly secrete apoE,
cell-associated apoE was not localized with the Golgi apparatus (Fig.
1, B and C). It is also noteworthy that little
apoE was detected at the cell surface (Fig. 1B).

View larger version (70K):
[in this window]
[in a new window]
|
Fig. 1.
ApoE expression and cellular
localization. A, cells and media were harvested after
24 h in serum-free DMEM, followed by the collection of media and
extraction of cell proteins. Equal amounts (40 µg of cell protein
extracts or 40 µl of 10× concentrated culture medium) of samples
were loaded onto SDS-12% polyacrylamide gels. ApoE was detected by
immunoblotting with monoclonal antibody E10 and the ECL reaction.
Lane 1, recombinant apoE (1 ng) as a positive control;
lane 2, E cell protein extract; lane
3, E+ cell protein extract; lane 4,
conditioned medium from E cells; lane 5,
conditioned medium from E+ cells. B and
C, shown is the dual labeling of permeabilized and fixed
E+ cells: endogenous apoE (rhodamine) (B) and
NBD-C6-labeled Golgi apparatus (C).
|
|
Interesting morphological changes were observed in E+
cells. Compared with E cells (Fig.
2A), E+ cells
(Fig. 2C) had shorter cell bodies, resulting in a more oval
shape, as well as less distinct nuclear boundaries when viewed by
phase-contrast microscopy and a prominent perinuclear accumulation of
phase-bright vesicles. Despite the above changes, similar to E cells (Fig. 2B), E+ cells
maintained a prominent actin filament network (Fig. 2D). In
E+ cells (Fig. 2G), the perinuclear accumulation
and increase in size of phase-bright vesicles relative to similar
vesicles in E cells (Fig. 2E) were more
apparent when viewed by differential interference contrast microscopy.
In E (Fig. 2, E and F) and
E+ (G and H) cells, these vesicles
were not co-localized with the Golgi apparatus. However, these vesicles
did stain positive with Nile red (data not shown), indicating the
presence of neutral lipid. Despite the apparent formation of larger
lipid-containing vesicles or droplets in E+ cells, there
was no measurable difference in whole cell lipid content (triglyceride
and cholesterol ester) between E+ and E cells
(data not shown).

View larger version (101K):
[in this window]
[in a new window]
|
Fig. 2.
ApoE expression alters cellular
morphology. Shown are the results from morphological
analyses of E (A, B, E,
and F) and E+ (C, D,
G, and H) cells by phase-contrast (A
and C; magnification × 100), fluorescence
(B and D, actin staining; F and
H, Golgi staining with NBD-C6;
magnification × 400), and differential interference contrast
(E and G; magnification × 400) microscopy.
Phase-contrast, differential interference contrast, and
NBD-C6 fluorescent images were gathered on live cells. The
actin network was visualized following staining of fixed cells with
actin-BODIPY-phallacidin. In E-H, perinuclear
localization of the Golgi apparatus is asymmetric and indicated by
asterisks. Neutral lipid-containing vesicles (see
"Results") are indicated by arrowheads.
|
|
The same morphological changes were seen in each of three independent
E+ clonal isolates, but were never seen in E
cells exposed to 10 µg/ml exogenous apoE, even after prolonged periods (up to 14 days). Thus, the presence of apoE within these fibroblasts had substantial effects on cellular architecture that could
not be mimicked by exposure to exogenous apoE.
ApoE Inhibits F111 Cell Proliferation--
To determine whether
apoE (both exogenous and endogenous) has a sustained effect on cell
proliferation, we compared the proliferation rate of E
cells, in the presence or absence of exogenous apoE, with that of
E+ cells over a period of 14 days (Fig.
3). Cells that expressed apoE had
significantly slower proliferation rates during mid-to-late log growth
(days 5-11) (Fig. 3A). Very similar results were seen when
exogenous apoE was added to the growth medium of E cells
(data not shown). In both cases, apoE increased population doubling
times by 30-50%, resulting in a 4-7-fold reduction in cell number on
days 5 and 7 (Fig. 3B). Despite the reduction in proliferation rates by day 14, the cell densities of apoE-exposed cultures were equal to the saturation density of cultures not exposed
to apoE. Therefore, apoE expression or addition to the culture medium
did not arrest cell proliferation.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 3.
ApoE slows proliferation by prolonging the
G1 phase of the cell cycle. Cells were plated on day 0 in the growth medium in the absence or presence of 10 µg/ml apoE. For
cells treated with exogenous apoE, fresh apoE was added at every media
change. Cells were trypsinized and counted (A and
B) or stained with propidium iodide and subjected to
fluorescence-activated cell sorter analysis (C). In
A, growth rates are shown for E ( )
and E+ ( ) cells. Asterisks represent time
points at which E and E+ cell numbers
differed significantly (p < 0.01). In B,
the data obtained at days 5 and 7 for E cells (with or
without exogenous (exog.) apoE) and E+ cells are
compared. Asterisks indicate that cell numbers differed
significantly from the untreated E control cells
(p < 0.05). In C, total DNA content was
quantified in E and E+ cells by measuring
propidium iodide staining 48 h after stimulating cells with 5%
calf serum. The number of cells in each phase of the cell cycle (based
on total DNA content) was divided by the total number of cells
monitored (gated total) and multiplied by 100 to derive percentages.
Over the course of these experiments, apoE expression was associated
with an increase in the percentage of cells in G1 (2N DNA
content). These results are from three parallel experiments. The
asterisk indicates that the percentage of cells in the
G1 phase of the cell cycle differed significantly between
E and E+ cells (p < 0.01).
The number sign indicates that the percentage of cells in
the G2 phase (4N DNA content) differed significantly
between E and E+ cells (p < 0.01).
|
|
The increased population doubling time of apoE-exposed cells was
associated with a prolongation of the G1 phase of the cell cycle. E and E+ cells were fixed, and their
DNAs were stained with propidium iodide 48 h after replating. Note
that plating densities for this experiment were considerably higher
than in the extended proliferation assays. As a result, by 48 h,
cell populations were in early-to-mid log growth. Relative DNA content
was quantified by flow cytometry (Fig. 3C). At 48 h
post-plating, 70% of E cells had a 2N DNA content (and
thus were in the G0/G1 phase of the cell
cycle), 18% had a 4N DNA content (G2/M phase), and 12%
had DNA levels intermediate between 2N and 4N (cells in S phase). In
contrast, 85% of the E+ cells were in
G0/G1, with compensatory decreases in the
number of cells in S phase (from 12 to 10%) and G2/M (from
18 to 5%; p < 0.05). There were few cells in either
population with less than 2N DNA levels, indicating that apoE
expression did not increase apoptotic DNA fragmentation.
ApoE Attenuates Growth Factor Signaling--
Prolongation of the
G1 phase of the cell cycle is frequently associated with
decreased responsiveness to mitogens. Indeed, several investigators
have demonstrated that exogenous apoE inhibits short-term proliferative
responses to mitogens of endothelial cells, Kaposi's sarcoma cells,
and smooth muscle cells (4-6). To see whether exogenous apoE and
endogenous apoE decreased F111 cell responsiveness to serum mitogens,
we measured [3H]thymidine incorporation into
E cells, into E+ cells, and into
E cells treated with exogenous apoE. Cells were arrested
in G0 by serum starvation (0.1% calf serum for 48 h)
and grown in 0.1 or 10% calf serum and 1 µC/ml
[3H]thymidine with or without exogenous apoE (10 µg/ml)
for 40 h, and incorporation of [3H]thymidine was
quantified. The results of these experiments uncovered two effects of
apoE. First, total incorporation of [3H]thymidine into
DNA and the -fold induction of [3H]thymidine
incorporation in response to serum were significantly reduced by apoE
(Fig. 4). Serum stimulated
[3H]thymidine incorporation into E cells by
25-fold. Exogenous apoE reduced the serum response of E
cells so that [3H]thymidine incorporation increased by
only 7-fold. Serum treatment had modest effects on E+
cells, increasing [3H]thymidine incorporation by 4-fold.
Second, in the presence of apoE (and in particular, endogenous apoE),
serum-starved cells continued to incorporate
[3H]thymidine into DNA. As a result, despite the
pronounced decreases in -fold stimulation in response to serum
treatment, apoE decreased overall thymidine incorporation only by 30%
(exogenous apoE) or by 50% (endogenous apoE). Taken together with the
previous data on population doubling times and cell cycle phase
distribution, we conclude that apoE reduces (but does not eliminate)
the ability of serum growth factors to drive progression of cells
through G1.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 4.
ApoE reduces serum-induced DNA
synthesis. Cells were maintained in medium containing 0.1% calf
serum (CS) for 48 h, at which time the medium was
replaced with fresh medium containing 0.1 or 10% calf serum, 1 µCi/ml [3H]thymidine, and 10 µg/ml exogenous
(exog.) apoE where indicated. After 40 h,
acid-insoluble radioactivity was measured ([3H]thymidine
incorporation).
|
|
ApoE Inhibits MAPK Activation, but Not c-fos Expression--
Among
the major mitogens present in serum are peptide growth factors that are
ligands for receptor tyrosine kinases, in particular, the potent
fibroblast mitogen platelet-derived growth factor (PDGF). Numerous
studies have established that growth factors drive G1 progression by activating cytosolic and nuclear protein kinases that
subsequently activate specific transcription factors. Key targets
include the p42 and p44 MAPKs and the c-fos proto-oncogene (39, 40). We determined whether apoE altered the overall levels of
serum- or PDGF-induced tyrosine phosphorylation, MAPK activity, and
c-fos expression. Cells (both E and
E+) were serum-starved for 48 h and then treated with
either 10 ng/ml PDGF or 10% calf serum (with or without exogenous
apoE) for 10 min. Both total tyrosine phosphorylation (Fig.
5A) and activated MAPK levels
(Fig. 5B) were monitored by immunoblotting. Serum
stimulation led to a rapid increase in tyrosine phosphorylation, in
particular, of multiple high molecular mass proteins (>175 kDa). PDGF treatment had a similar, although less pronounced effect on
total tyrosine phosphorylation. The most notable differences between
serum and PDGF effects occurred in the high molecular mass proteins,
consistent with the view that these changes likely represent
autophosphorylation of a variety of receptor tyrosine kinases in
response to the mixture of polypeptide growth factors present in serum.
Similar responses to both serum stimulation and PDGF stimulation were
seen in E+ and E cells and in E
cells treated with exogenous apoE and PDGF.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 5.
Effects of apoE on growth factor
signaling. E and E+ cells were
maintained in 0.1% calf serum (CS) for 48 h. Cells
were then stimulated with 10 ng/ml PDGF or 10% calf serum in the
presence or absence of 10 µg/ml exogenous (exog.) apoE for
10 min. Tyrosine phosphorylation (A) and MAPK activation
(B; amount of phospho-MAPK (MAPK-PO4)
relative to the amount of total MAPK (MAPK-tol)) were
assessed by immunoblotting. In C, serum-starved
E and E+ cells were treated with 0.1 or 3%
calf serum ± 10 µg/ml exogenous apoE for 30 min, after which
total RNA was extracted, and c-fos and L30 mRNA levels
were determined by Northern blot analysis. ApoE (both exogenous and
endogenous) prevented MAPK activation without detectably
affecting tyrosine phosphorylation or c-fos mRNA
expression.
|
|
When we looked specifically at activation of p42/p44 MAPKs by serum and
PDGF, a different pictured emerged (Fig. 5B). Stimulation of
E cells resulted in activation of MAPK in a manner that
paralleled overall changes in tyrosine phosphorylation. Either in
E+ cells or when added to E cells, apoE
dramatically reduced the activation of MAPK. This was true in response
to both PDGF and serum stimulation.
In many situations, following activation in the cytosol, MAPKs
translocate to the nucleus and contribute to transcriptional regulation of target genes. Following mitogenic stimulation of resting
cells, critical nuclear targets are the immediate-early growth
response genes, including the c-fos proto-oncogene.
Increased c-fos mRNA levels were seen within 15 min of
stimulating serum-starved E cells as well as
E+ cells. Peak c-fos mRNA levels were
reached 30 min after stimulation. Despite the effects of apoE on
[3H]thymidine incorporation, cell cycle progression, and
MAPK documented above, no inhibition of c-fos induction was
observed in the presence apoE (Fig. 5C).
Vogel et al. (4) previously proposed that apoE
inhibits proliferation by competing with fibroblast growth factors for
heparin binding. This model leads to the prediction that at a fixed
concentration of apoE, increased levels of growth factor should
increase proliferation. We tested this prediction by measuring the
proliferation of E cells, of E cells
treated with apoE (10 µg/ml), and of E+ cells in
different serum concentrations (Fig. 6).
The proliferation rate of E cells, either in the absence
or presence of exogenous apoE, increased incrementally in response to
increases in serum from 2.5 to 10%. At days 7 and 9, each 2-fold
increase in serum concentration resulted in an ~1.6-fold increase in
cell number (Fig. 6, A and B). In contrast, the
proliferation rate of E+ cells was much less dependent on
serum concentration. As shown in Fig. 6C, the increase in
serum concentration from 2.5 to 10% did not significantly increase
cell number on day 7 or 9. Note that the number of E
cells is three to seven times more than the number of E+
cells under each condition at days 7 and 9. Therefore, although it is
possible that competition with fibroblast growth factor or other serum
factors for heparin-binding sites might explain part of the
anti-proliferative effect of apoE, it is unlikely to account for all of
the actions of apoE, in particular, when apoE is expressed
endogenously.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 6.
Endogenous apoE inhibits serum effects on
cell proliferation. E cells (A),
E cells treated with 10 µg/ml exogenous apoE
(B), and E+ cells (C) were grown in
medium supplemented with 2.5% (open bars), 5%
(hatched bars), or 10% (closed bars) calf serum
(CS). After day 7 or 9, total cell numbers were counted. For
each 2-fold increase in serum concentrations, E cell
numbers increased (~1.6-fold), whereas E+ cell numbers
were unaffected by serum concentration. Asterisks indicate
that the number of E cells differed significantly between
the 2.5 and 5% calf serum groups, and number signs indicate
that the numbers differed between the 5 and 10% groups
(p < 0.05). Note that at all serum concentrations,
there were significantly fewer E+ cells than
E cells (p < 0.05; note the differences
in the scale of the y axes in A and
C).
|
|
ApoE Stimulates DNA Synthesis in the Absence of Serum--
In the
presence of apoE, F111 cells had elevated levels of DNA synthesis in
the absence of serum (Fig. 4, compare open bars). This
latter result was examined in more detail (Fig.
7). First, we confirmed that apoE
elevated basal [3H]thymidine incorporation in the absence
of calf serum using three independent isolates (one pool of many
clones, E -1 and E+-1; and two isolated
clones, E -2, E -3, E+-2, and
E+-3) of transfected cells expressing hygromycin resistance
or expressing both hygromycin resistance and apoE. For the control cell
lines, basal [3H]thymidine incorporation ranged from 4500 to 8000 dpm incorporated per dish. Addition of exogenous apoE variably
increased [3H]thymidine incorporation, with responses
ranging from 110% in clone E -1 to a 300% increase (from
5200 to 16,100 dpm) in clone E -3. In clonal isolates of
apoE-expressing cells, basal [3H]thymidine incorporation
was dramatically elevated. In these cells, incorporation ranged from
11,200 dpm/dish for the uncloned pool to ~30,000 dpm/dish for the
clonal isolates. ApoE expression and secretion were quantified in the
two monoclonal E+ cell lines. The two clones had comparable
levels of cell-associated apoE (27.7 and 29.2 ng of apoE/mg of cell
protein, respectively); however, the level of apoE in the conditioned
medium from clone E+-3 (1700 ng of apoE/mg of cell protein)
was about five times higher than in the medium from clone
E+-2 (320 ng of apoE/mg of cell protein). Despite
differences in apoE secretion, similar levels of DNA synthesis were
observed in the two apoE-expressing clones. Therefore, apoE has two
apparently disparate effects on proliferation. On the one hand, apoE
allowed serum-deprived cells to remain in the cell cycle. On the other hand, apoE extended the time of G1 progression, resulting
in longer population doubling times. This effect was associated with
significantly attenuated responses to serum growth factors and/or
PDGF.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 7.
ApoE enhances DNA synthesis in serum-deprived
cells. Cells were maintained in 0.1% calf serum for
48 h and then incubated in fresh medium with 0.1% calf serum
(CS), 1 µCi/ml [3H]thymidine, and 10 µg/ml
exogenous apoE (E) where indicated for an additional 40 h. In parallel, apoE levels in cell extracts and conditioned media from
clones E+-2 and E+-3 were quantified by
densitometric scanning of immunoblots. These data are shown at the top
and are expressed as nanograms of apoE. [3H]Thymidine
incorporation was measured as described under "Results."
Open bars, E cells (E -1 pooled
clones and E -2 and E -3 clonal isolates);
hatched bars, E cells treated with
exogenous apoE; closed bars, E+ cells
(E+-1 pooled clones and independent E+-2 and
E+-3 clonal isolates). N.D., not
determined.
|
|
 |
DISCUSSION |
In this study, we examined both long- and short-term effects of
apoE on cell proliferation. In addition, we have systematically compared the effects of apoE added to growth medium with the effects of
stably expressing apoE in target cells. Specifically, this study
demonstrates that both endogenous apoE and exogenous apoE (a) decrease proliferation rates (but not to 0) over an
extended period, (b) inhibit activation of MAPKs and
stimulation of DNA synthesis by serum, and (c) increase DNA
synthesis in serum-deprived cells.
Our results also confirm the data of others (4-6) demonstrating that
apoE, independently of its role in lipid transport and metabolism,
exerts an anti-proliferative effect on cells and attenuates serum
growth factor signaling. However, our results extend these previous
studies in three important ways. First, we demonstrated that the
effects of exogenous apoE and endogenous apoE differ in both
quantitative and qualitative ways. These differences are likely to
reflect underlying differences in the mechanism of apoE action when
presented to cells in these distinct ways. Second, we demonstrated that
the effects of apoE are prolonged. A significant finding in this
respect is that apoE exposure does not result in growth arrest.
Although apoE prolongs progression through the G1 phase of
the cell cycle, it does not cause cells to exit the cycle and become
quiescent or to stop at either the G1/S or G2/M checkpoint. Third, apoE (in particular, endogenous apoE) dissociates serum growth factor signaling from cell proliferation. This is evident
when one considers both the inhibitory effect of apoE on
serum-stimulated progression from G0 through G1
and into S phase and the observation that E+ cells continue
to synthesize significant amounts of DNA in the near absence of serum
growth factors.
Do Exogenous ApoE and Endogenous ApoE Act via Distinct
Mechanisms?--
In a previous study comparing the effects of
exogenous apoE and endogenous apoE on lipoprotein uptake and metabolism
by mouse macrophages, we demonstrated clear differences in the response to apoE from these different sources (28, 29). We attributed the
difference in action to the restriction of exogenous apoE and
endogenous apoE to distinct subcellular compartments; exogenous apoE
was detected in endocytic vesicles, whereas endogenous apoE was found
in the secretory pathway. In this study, exogenous apoE and endogenous
apoE shared the ability to slow proliferation rates, to elevate (or
sustain) basal DNA synthesis in low serum, and to inhibit acute growth
factor signaling. Endogenous apoE was more effective than exogenous
apoE in eliciting the first two responses. It is clear that endogenous
apoE can affect additional cellular functions that are not sensitive to
the amount of exogenous apoE used in this study, including changes in
cellular morphology and the reduction in the requirement for serum
mitogens. The broader action of endogenous apoE might result from its
ability to target an additional signaling pathway (other than leading
to MAPK activation). Recent studies have shown that apoE may inhibit
cell proliferation through receptor-independent mechanisms (41), but
modulate cell migration through apoE receptor-dependent
pathways, although which of the family of apoE receptors is involved is
not known (41, 42). Whether similar mechanisms are responsible for the
effects of apoE on cell proliferation and the morphological changes
observed in this study requires further investigation.
It is possible to explain the enhanced effectiveness of endogenous
versus exogenous apoE on common targets by proposing that higher and more sustained concentrations of apoE at the cell surface were achieved following local synthesis and secretion than were achieved following addition of exogenous apoE to the culture medium. Human plasma contains ~36 µg/ml apoE, largely bound to lipoproteins (43). The minimal exogenous apoE concentration that consistently inhibited cell proliferation in our studies was 5 µg/ml, whereas E+ cells secreted on average only ~100 ng of apoE/ml/day.
ApoE is a heparin-binding protein and therefore would be expected to
stay bound to cell-surface heparin-containing proteoglycans. Such tight binding would result in an underestimation of the levels of apoE secreted, and the effective concentration acting on the cell surface would be significantly higher. However, immunological localization of
apoE in E+ cells does not support this; the majority of
apoE appeared to be cytoplasmic and not cell surface-associated (Fig.
1B). In macrophages, endogenous apoE and exogenous apoE
follow separate intracellular trafficking routes. Endogenous apoE is
associated with Golgi structures, whereas exogenous apoE is found in
endocytic vesicles (28). In the E+ cells studied here,
there was only minimal overlap between immunoreactive apoE and staining
with Golgi markers (Fig. 1, B and C). Although these assays do not afford the resolution necessary to determine whether the bulk of endogenous apoE was cytosolic or vesicular (endocytic or pre-Golgi secretory), they raise the possibility that a
significant fraction of endogenous apoE might be in a non-secretory compartment. We suggest it is likely that this intracellular apoE interacts with cytoskeletal components that are not accessible to
exogenous apoE and that these interactions cause reorganization of
cytoskeletal structures and alter signal transduction.
How Does ApoE Affect Proliferation?--
Two possible mechanisms
have been proposed to account for the anti-proliferative affects of
apoE. In one, apoE acts directly to inhibit growth factor signaling.
Browning et al. (5) have proposed that apoE, by
virtue of its high affinity for heparin sulfate, interferes with growth
factor signaling by competing for cell-surface binding sites. This
model is unlikely to explain our results for two reasons. First, this
mechanism should be limited to inhibiting signaling by mitogens that
depend on heparin sulfate binding for efficient signaling,
e.g. the fibroblast growth factors. However, in our assays,
apoE was broadly effective, blocking the action of the mixture of
mitogens present in calf serum and the action of purified PDGF. Second,
apoE (exogenous and endogenous) inhibited MAPK activation, but failed
to prevent either serum or purified PDGF stimulation of tyrosine
phosphorylation or induction of c-fos expression. We showed
previously that transcriptional activation of c-fos in F111
cells depends predominantly on signaling to the nucleus via
phosphatidylinositol 3-kinase and c-Jun N-terminal kinase (21).
Therefore, the different effect of apoE on MAPK activation and
c-fos induction indicates that only a specific subset of
signaling pathways activated by receptor tyrosine kinases are affected
by apoE.
Paka et al. (44) have proposed an alternative mechanism in
which apoE exerts a positive effect on synthesis of the heparin sulfate
proteoglycan perlecan, which exerts the measured anti-proliferative effects on apoE. Although we cannot rule out a role for perlecan in
mediating the sustained effects of apoE (especially in E+
cells), the ability of exogenous apoE to rapidly inhibit growth factor
signaling is not compatible with the delay (24-48 h) required for
increased expression and synthesis of perlecan (44).
At present, we do not know how apoE disrupts growth factor signaling.
An important clue might come from our demonstration that although apoE
expression slows proliferation and inhibits mitogenic signaling, it
does not result in growth arrest. Indeed, apoE expression enhances
aspects of proliferation, notably DNA synthesis in the absence of
external mitogens. Two precedents for such apparently dichotomous
activities are worth noting. The first precedent comes from results
that closely parallel ours, in which Chen and Gardner (45) demonstrated
that retinoic acid has the ability both to stimulate mitogenesis of
aortic smooth muscle cells and to inhibit the mitogenic action of
endothelin on these same cells. Thus, retinoic acid inhibits signaling
required for early G1 progression (mitogen activation of
MAPK), but increases expression of cyclin D, which is required for the
progression from late G1 into S phase. The second precedent
comes from studies on oncogenic transformation. Acute expression of
many oncogenes such as v-src and v-ras activates
mitogenic signaling cascades and active transcription of target genes.
However, in cells that have been transformed by stable expression of
these proteins, signaling in response to exogenous growth factors is
inhibited (46-48). It is possible that endogenous apoE acts in an
analogous, albeit much more constrained manner, resulting in uncoupling
of cell cycle progression from dependence on positive extracellular signals.
Abnormalities in the control of cell proliferation and differentiation
are associated with a number of diseases, including atherosclerosis.
Hyperproliferation of smooth muscle cells contributes to the
progressive formation of atherosclerotic plaques (31). Accumulation of
apoE in atherosclerotic lesions (32) is believed to be anti-atherogenic
by promoting cellular cholesterol efflux and increasing lipid
metabolism (7, 10). The previous observation that apoE inhibits smooth
muscle cell proliferation (6) and our current finding that the
anti-proliferative effect of apoE is sustained over long periods
provide an additional mechanism for the anti-atherogenic action of
apoE.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grants HL40404 and CA79737, National Livestock and Meat Board Grant 6-41809, an American Institute of Nutrition predoctoral fellowship (to
Y.-Y. H.), and American Cancer Society Grant RPG-95-024-03.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Present address: Dept. of Neurology, Columbia University, NI 9-100, 710 W. 168th St., New York, NY 10032.
Present address: Dept. of Neuroscience, Johns Hopkins
University School of Medicine, PCTB 1004, 725 N. Wolfe St., Baltimore, MD 21205.

To whom correspondence should be addressed: Inst. of Human
Nutrition, Columbia University, HHSC 5-503, 701 W. 168th St., New York,
NY 10032. Tel.: 212-305-2107, Fax: 212-305-3079; E-mail: dat1@columbia.edu.
Published, JBC Papers in Press, September 10, 2001, DOI 10.1074/jbc.M105325200
 |
ABBREVIATIONS |
The abbreviations used are:
apoE, apolipoprotein
E;
MAPK, mitogen-activated protein kinase;
DMEM, Dulbecco's modified
Eagle's medium;
PBS, phosphate-buffered saline;
NBD-C6, NBD-C6-ceramide,
6-(cN-(7-nitrobenz-z-oxa-1,3-diazol-4-gl)amino)hexanoyl)sphingosine;
MOPS, 3-(N-morpholino)propanesulfonic acid;
PDGF, platelet-derived growth factor.
 |
REFERENCES |
| 1.
|
Mahley, R. W.
(1988)
Science
240,
622-630[Abstract/Free Full Text]
|
| 2.
|
Roses, A. D.,
Saunders, A. M.,
Corder, E. H.,
Pericak-Vance, M. A.,
Han, S. H.,
Einstein, G.,
Hulette, C.,
Schmechel, D. E.,
and Huang, D.
(1995)
Arzneim. Forsch.
45,
413-417[Medline]
[Order article via Infotrieve]
|
| 3.
|
Lin, C. Y.,
Lucas, M.,
and Mazzone, T.
(1998)
J. Lipid Res.
39,
293-301[Abstract/Free Full Text]
|
| 4.
|
Vogel, T.,
Guo, N.,
Guy, R.,
Drezlich, N.,
Krutzsch, H. C.,
Blake, D. A.,
Panet, A.,
and Roberts, D. D.
(1994)
J. Cell. Biochem.
54,
299-308[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Browning, P. J.,
Roberts, D. D.,
Zabrenetzky, V.,
Bryant, J.,
Kaplan, M.,
Washington, R. H.,
Panet, A.,
Gallor, R. C.,
and Vogel, T.
(1994)
J. Exp. Med.
180,
1949-1954[Abstract/Free Full Text]
|
| 6.
|
Ishigami, M.,
Swertfeger, D. K.,
Granholm, N. A.,
and Hui, D. Y.
(1998)
J. Biol. Chem.
273,
20156-20161[Abstract/Free Full Text]
|
| 7.
|
Mazzone, T.,
and Reardon, C.
(1994)
J. Lipid Res.
35,
1345-1353[Abstract]
|
| 8.
|
Basu, S. K.,
Brown, M. S.,
Havel, R. J.,
and Goldstein, J. L.
(1981)
Proc. Natl. Acad. Sci. U. S. A.
78,
7545-7549[Abstract/Free Full Text]
|
| 9.
|
Dory, L.
(1991)
J. Lipid Res.
32,
783-792[Abstract]
|
| 10.
|
Schweigelshohn, B.,
Presley, J. F.,
Gorecki, M.,
Vogel, T.,
Carpentier, Y. A.,
Maxfield, F. R.,
and Deckelbaum, R. J.
(1995)
J. Biol. Chem.
270,
1761-1769[Abstract/Free Full Text]
|
| 11.
|
Weisgraber, K. H.,
Rall, S. C.,
Mahley, R. W.,
Marcel, Y. L.,
and Sparrow, J. T.
(1986)
J. Biol. Chem.
261,
2068-2076[Abstract/Free Full Text]
|
| 12.
|
Dahan, S.,
Ahluwalia, J. P.,
Wong, L.,
Posner, B. I.,
and Bergeron, J. J.
(1994)
J. Cell Biol.
127,
1859-1869[Abstract/Free Full Text]
|
| 13.
|
Granot, E.,
and Eisenberg, S.
(1995)
Atherosclerosis
114,
115-122[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Majack, R. A,
Castle, C. K.,
Goodman, L. V.,
Weisgraber, K. H.,
Mahley, R. W.,
Shooter, E. M.,
and Gebicke-Haerter, P. J.
(1988)
J. Cell Biol.
107,
1207-1213[Abstract/Free Full Text]
|
| 15.
|
Auwerx, J. H.,
Deeb, S.,
Brunzell, J. D.,
Peng, R.,
and Chait, A.
(1988)
Biochemistry
27,
2651-2655[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Crespo, P.,
Delgado, M. D.,
Gomez-Casares, M. T.,
Cuadrado, M. A.,
Richard, C.,
and Leon, J.
(1993)
Leuk. Res.
17,
771-776[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Reyland, M. E.,
and Williams, D. L.
(1991)
J. Biol. Chem.
266,
21099-21104[Abstract/Free Full Text]
|
| 18.
|
Reyland, M. E.,
Prack, M. M.,
and Williams, D. L.
(1992)
J. Biol. Chem.
267,
17933-17938[Abstract/Free Full Text]
|
| 19.
|
Talmage, D. A.,
and Lackey, R. S.
(1992)
Oncogene
7,
1837-1845[Medline]
[Order article via Infotrieve]
|
| 20.
|
Talmage, D. A.,
Riney, C.,
and Benjamin, T. L.
(1991)
Cell Growth Differ.
2,
51-58[Abstract]
|
| 21.
|
Chen, Y.,
Freund, R.,
Listerud, M.,
Wang, Z.,
and Talmage, D. A.
(1999)
Oncogene
18,
139-148[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
| Deleted in proof
|
| 23.
| Deleted in proof
|
| 24.
| Deleted in proof
|
| 25.
| Deleted in proof
|
| 26.
| Deleted in proof
|
| 27.
| Deleted in proof
|
| 28.
|
Ho, Y.-Y.,
Al-Haideri, M.,
Mazzone, T.,
Vogel, T.,
Presley, J. F.,
Sturley, S.,
and Deckelbaum, R. J.
(2000)
Biochemistry
39,
4746-4754[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
| Mamdouh, Z., Deckelbaum, R. J., Seo, T., Maxfield, F. R.,
Vogel, T., and Al-Haideri, M. (2000) Circulation
98, II-87 (Abstr. 420)
|
| 30.
| Deleted in proof
|
| 31.
|
Garcia, J. H.,
and Khang-Loon, H.
(1996)
Neuroimaging Clin. N. Am.
6,
801-810[Medline]
[Order article via Infotrieve]
|
| 32.
|
Rosenfeld, M. E.,
Butler, S.,
Ord, V. A.,
Lipton, B. A.,
Dyer, C. A.,
Curtiss, L. K.,
Palinski, W.,
and Witztum, J. L.
(1993)
Arterioscl. Thromb.
13,
1382-1389[Abstract/Free Full Text]
|
| 33.
|
Mazzone, T.,
Pustelnikas, L.,
and Reardon, C. A.
(1992)
J. Biol. Chem.
267,
1081-1087[Abstract/Free Full Text]
|
| 34.
|
Khuri, F. R.,
Cho, Y.,
and Talmage, D. A.
(1996)
Cell Growth Differ.
7,
595-602[Abstract]
|
| 35.
|
Radloff, R.,
Bauer, W.,
and Vinograd, J.
(1967)
Proc. Natl. Acad. Sci. U. S. A.
57,
1514-1521[Free Full Text]
|
| 36.
|
Chen, C.,
and Okayama, H.
(1988)
BioTechniques
6,
632-638[Medline]
[Order article via Infotrieve]
|
| 37.
|
Seitz, W. R.
(1984)
Clin. Biochem.
17,
120-125[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Feinberg, A. P.,
and Vogelstein, B.
(1983)
Anal. Biochem.
132,
6-13[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
De Vivo, M.,
and Iyengar, R.
(1994)
J. Biol. Chem.
269,
19671-19674[Abstract/Free Full Text]
|
| 40.
|
Thommes, K. B.,
Hoppe, J.,
Vetter, H.,
and Sachinidis, A.
(1996)
Exp. Cell Res.
226,
59-66[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Swertfeger, D. K.,
and Hui, D. Y.
(2001)
J. Biol. Chem.
276,
25043-25048[Abstract/Free Full Text]
|
| 42.
|
Herz, J.,
and Beffert, U.
(2000)
Nat. Rev. Neurosci.
1,
51-58[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Rifai, N.,
and Silverman, L. M.
(1987)
Clin. Chim. Acta
163,
207-213[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Paka, L.,
Goldberg, I. J.,
Obunike, J. C.,
Choi, S. Y.,
Saxena, U.,
Goldberg, I. D.,
and Pillarisetti, S.
(1999)
J. Biol. Chem.
274,
36403-36408[Abstract/Free Full Text]
|
| 45.
|
Chen, S.,
and Gardner, D. G.
(1998)
J. Clin. Invest.
102,
653-662[Medline]
[Order article via Infotrieve]
|
| 46.
|
Osei-Frimpong, J.,
Sepulveda, J.,
Rangdaeng, S.,
and Lebovitz, R. M.
(1994)
Mol. Carcinog.
10,
72-81[Medline]
[Order article via Infotrieve]
|
| 47.
|
Lucibello, F. C.,
Lowag, C.,
Neuberg, M.,
and Muller, R.
(1989)
Cell
59,
999-1007[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Sassone-Corsi, P.,
Sisson, J. C.,
and Verma, I. M.
(1988)
Nature
334,
314-319[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
D. E. Dove, M. F. Linton, and S. Fazio
ApoE-mediated cholesterol efflux from macrophages: separation of autocrine and paracrine effects
Am J Physiol Cell Physiol,
March 1, 2005;
288(3):
C586 - C592.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-C. Chen, G. Pohl, T.-L. Wang, P. J. Morin, B. Risberg, G. B. Kristensen, A. Yu, B. Davidson, and I.-M. Shih
Apolipoprotein E Is Required for Cell Proliferation and Survival in Ovarian Cancer
Cancer Res.,
January 1, 2005;
65(1):
331 - 337.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. W.Q. Moore, B. Zhu, D. G. Kuhel, and D. Y. Hui
Vascular Apolipoprotein E Expression and Recruitment from Circulation to Modulate Smooth Muscle Cell Response to Endothelial Denudation
Am. J. Pathol.,
June 1, 2004;
164(6):
2109 - 2116.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Lutz, J. Nimpf, M. Jenny, K. Boecklinger, C. Enzinger, G. Utermann, G. Baier-Bitterlich, and G. Baier
Evidence of Functional Modulation of the MEKK/JNK/cJun Signaling Cascade by the Low Density Lipoprotein Receptor-related Protein (LRP)
J. Biol. Chem.,
November 1, 2002;
277(45):
43143 - 43151.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Boucher, P. Liu, M. Gotthardt, T. Hiesberger, R. G. W. Anderson, and J. Herz
Platelet-derived Growth Factor Mediates Tyrosine Phosphorylation of the Cytoplasmic Domain of the Low Density Lipoprotein Receptor-related Protein in Caveolae
J. Biol. Chem.,
May 3, 2002;
277(18):
15507 - 15513.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|